Latest Celldex Therapeutics Inc (CLDX) Headlines
Post# of 98
Posted On: 03/13/2014 6:47:15 AM
Latest Celldex Therapeutics Inc (CLDX) Headlines
Northwest Bio's German Smokescreen Obscures DCVax Problems
at The Street - Tue Mar 11, 1:44PM CDT
Northwest Bio received good news from Germany in February but didn't tell investors until Monday.
Biotech Earnings Checkup: CLDX, DNDN, OPX
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Earnings are the lifeblood of a company. They speak to a company's past, present, and most importantly for investors, future. And they give an important window into the overall health of a company. So, with that in mind, let's dig into the earnings...
Personalized Medicine and Companion Diagnostic Market - 2014 Gives Details of their Operations, Products, Financials and Business Strategy
M2 - Thu Mar 06, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpc89x/personalized) has announced the addition of the "Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 263 tables & figures over 224 pages. The personalized medicine (global) market is presented as follows: -By Company -By Geography -By Segment -By Sub-market A wealth of financial data & business strategy information is provided including: -Up-to-date company financials, sales & revenue figures -Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies -Business Model Strategies for Providers. Provider Systems and Academic Medical Centres -Business Model Strategies for Payers & Governments -Private and Public Funding and Personalized Medicine Reimbursement -Revisions to Current Payment Systems and intellectual property -How to Gain Market Penetration in the EU -Cost-effectiveness and Business Value of Personalized Medicine -Consumer genomics and POC market -Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) -Comprehensive account of company product portfolios & kits This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. -23andMe -Affymetrix -Astex Pharmaceuticals -Atossa Genetics -CuraGen -Celera Corporation (Quest Diagnostics) -Celldex Therapeutics -deCode Genetics (Amgen) -Illumina -Genelex -Myriad -Nodality -Qiagen This report tackles key concerns to the personalized medicine market such as: -Lack of regulatory policy and legislation in the US and Europe -Reimbursement schemes and payers concerns -Transition of investigational diagnostic assays and therapeutics to clinical practice -Direct to consumer (DTC) test kits and implications for the public This detailed report is supported with 263 figures and tables over 224 pages and profiles the main pharmacos in personalized medicine. For more information visit http://www.researchandmarkets.com/research/rp...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Celldex Posts Narrower-Than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 10:30AM CST
Celldex' loss narrows in Q4
Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX)
at The Street - Tue Mar 04, 8:46AM CST
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Celldex Therapeutics (CLDX) in Focus: Stock Tumbles 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:56AM CST
Celldex Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell over 10% on the day.
American Realty Capital Properties and Cole Capital(TM) Name Michael Ezzell to Lead Private Capital Management Business
PR Newswire - Tue Mar 04, 5:00AM CST
American Realty Capital Properties, Inc. ("ARCP") and Cole Capital(TM), ARCP's private capital management business, jointly announced today the appointment of Michael Ezzell as Executive Vice President of Private Capital Markets.
Why Celldex Therapeutics Inc. Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 03, 12:27PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Celldex Therapeutics , a predominantly...
Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due
at The Street - Mon Mar 03, 9:32AM CST
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
Celldex Reports Fiscal 2013 Business/Financial Results and Outlines 2014 Strategy
GlobeNewswire - Mon Mar 03, 7:03AM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2013 and outlined the Company's major clinical development goals for 2014.
Celldex to Report Fourth Quarter and Fiscal 2013 Business/Financial Results and Host 2014 Strategy Conference Call
GlobeNewswire - Tue Feb 25, 12:30PM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year end 2013 financial results on Monday, March 3, 2014 before the U.S. financial markets open. Celldex executives will host a conference call at 8:30 a.m. ET on the same day to discuss 2013 financial and business results and to provide an update on key 2014 objectives.
Sumtra to add approval of property sale to annual meeting agenda
CNW Group - Sat Feb 22, 12:03PM CST
Sumtra Diversified Inc. (NEX Board: YSU.H) ("Sumtra" or the "Company") announced today that it plans to ask shareholders to also consider the approval of the sale of certain real property held by Sumtra (the "Property Sale") as other business at the Company's upcoming annual and special meeting of shareholders to be held in Toronto on Tuesday, February 25, 2014 (the "Meeting").
Celldex Therapeutics Rises 9.74% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Feb 21, 4:32PM CST
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $28.93 to a high of $31.83. Yesterday, the shares gained 9.7%, which took the trading range above the 3-day high of $29.14 on volume of 4.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
US Cancer Vaccine Market Outlook 2018 Research Report
M2 - Fri Feb 14, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/vmrhtt/us_cancer_vaccine) has announced the addition of the "US Cancer Vaccine Market Outlook 2018" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. The vaccine market, specifically the cancer vaccine market has remained resilient to the global economic crisis in contrast to many life science sectors, which were severely impacted. Owing to drying pipelines and increasing pressure from patent expirations, the big pharma companies recognized the vaccine market as a potential resource of investment. Cancer vaccines are known to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the demand for these vaccines. The US cancer vaccine market was estimated to be worth USD 14 billion in 2012. The market is expected to witness an increase of 1.5 million people being diagnosed with cancer annually. With such a rapid increase in the incidence, the US cancer vaccine market is expected to grow at a CAGR of 10% to surpass USD 20 billion by 2018. The market for cancer vaccine is in its growth stage in the US and has great opportunities for entry. The USA alone accounts for a dominating share of 50% as compared to a combined share of 50% accounted for by Europe and other regions. US Cancer Vaccine Market Outlook 2018 gives a comprehensive insight on following issues related to cancer vaccine market development in US: - Cancer Incidence & Prevalence - Cancer Vaccine Market Overview - Cancer Vaccine Pricing & Reimbursement Policy - Cancer Vaccine with Orphan Status - Cancer Vaccine Pipeline by Indication & Phase - Market Regulations - Company Overview & Vaccine Pipeline Key Topics Covered: US Cancer Incidence & Prevalence US Cancer Vaccine Market Outlook US Cancer Vaccine Market Dynamics US Cancer Vaccine Pipeline by Indication US Cancer Vaccine Pipeline by Clinical Phase US Cancer Vaccine Market Regulations Competitive Landscape: Business Overview & Vaccine Pipeline List of Tables and Figures Companies Mentioned - Aduro BioTech - Antigen Express - Bavarian Nordic - Celldex Therapeutics - Dendreon - GSK - Galena Biopharma - Merck & Co - Oxford BioMedica For more information visit http://www.researchandmarkets.com/research/vm...er_vaccine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Use Options For A Chance To Buy CLDX At A 62% Discount
at The Street - Thu Feb 13, 10:42AM CST
Looking back to 71 days ago, Celldex Therapeutics priced a 7,000,000 share secondary stock offering at $24.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the...
Monoclonal Antibodies Market in Breast Cancer to 2019: Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth
M2 - Thu Feb 13, 10:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/3fr5l8/monoclonal) has announced the addition of the "Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth" report to their offering. The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of these have also received further approvals in the early setting in order to improve long-term remission rates. The market is currently led by the HER-2 inhibitor Herceptin, which achieved global sales amounting to $6.2 billion in 2012. Over the forecast period from 2012 to 2019, the two novel HER-2 inhibitors, Kadcyla and Perjeta, are expected to achieve strong market penetration due to their appreciable incremental efficacy benefits. Additionally, the market conditions are currently favorable towards mAbs, with a low rate of price depreciation following patent expiry and a high rate of inflation for specialty pharmaceuticals in the US. As a result of this, and despite the empty Phase III pipeline, the authors believe that the global market across the leading eight countries have the potential to grow to a value of $10.6 billion by 2019. Key Topics Covered: 1. Tables & Figures 2 Introduction 3 Marketed Products 3.1 Herceptin (Trastuzumab) - Hoffmann La Roche 3.2 Avastin (Bevacizumab) - Hoffmann La Roche 3.3 Kadcyla (Trastuzumab Emtansine) - Hoffmann La Roche 3.4 Perjeta (Pertuzumab) - Hoffmann La Roche 3.5 Xgeva (denosumab) - Amgen 3.6 Heat Map for Marketed Products 3.7 Conclusion 4 Pipeline for Breast Cancer Monoclonal Antibody Therapeutics 4.1 Overall Pipeline 4.2 Mechanisms of Action 4.3 Clinical Trials 4.3.1 Attrition Rate 4.3.2 Clinical Trial Size 4.3.3 Duration 4.3.4 Clinical Trial End-points 4.4 Promising Drug Candidates in the Pipeline 4.4.1 CDX-011 (glembatumumab vedotin) - Celldex Therapeutics 4.4.2 Metmab (onartuzumab) - Hoffman La Roche 4.4.3 Hu3S193 - Recepta Biopharma 4.4.4 MM-121 - Merrimack Pharmaceuticals 4.4.5 IMC-18F1 (Icrucumab) - Eli Lilly 4.4.6 Rexomun (Ertumaxomab) - Fresenius Biotech 4.4.7 Medi-573 (Dusigitumab) - Medimmune 4.4.8 MK-0646 (Dalotuzumab) - Merck and Co 4.4.9 LY3012217 (Cixutumumab) - Eli Lilly 4.5 Conclusion 5 Market Forecast to 2019 5.1 Global 5.2 US 5.3 Canada 5.4 Europe 5.5 Japan 5.6 Drivers and Barriers 6 Deals and Strategic Consolidations 7 Appendix For more information visit http://www.researchandmarkets.com/research/3fr5l8/monoclonal
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013
M2 - Thu Feb 13, 2:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/dcl2zl/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013" report to their offering. 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM). Key Topics Covered: Introduction Recurrent Glioblastoma Multiforme (GBM) Overview Therapeutics Development Clinical Stage Products Early Stage Products Drug Profiles bosutinib - Drug Profile axitinib - Drug Profile onartuzumab - Drug Profile dacomitinib - Drug Profile rindopepimut - Drug Profile VB-111 - Drug Profile ANG-1005 - Drug Profile AT-101 - Drug Profile vorinostat - Drug Profile buparlisib hydrochloride - Drug Profile pazopanib hydrochloride - Drug Profile memantine hydrochloride - Drug Profile galunisertib - Drug Profile G-200 - Drug Profile ERC-1671 - Drug Profile lenvatinib - Drug Profile trebananib - Drug Profile TB-403 - Drug Profile nabiximols - Drug Profile golvatinib - Drug Profile ARC-100 - Drug Profile New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile vocimagene amiretrorepvec flucytosine ER - Drug Profile golvatinib lenvatinib - Drug Profile ICT-121 - Drug Profile BTSC mRNA Loaded Dendritic Cell Vaccine - Drug Profile AZD-7451 - Drug Profile DNX-2401 - Drug Profile OS-2966 - Drug Profile Recurrent Glioblastoma Multiforme (GBM) - Recent Pipeline Updates Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned F. Hoffmann-La Roche Ltd. Amgen Inc. AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Agenus, Inc. Merck & Co., Inc. Novartis AG Eisai Co., Ltd. Pfizer Inc. GW Pharmaceuticals plc Celldex Therapeutics, Inc. ImmunoCellular Therapeutics, Ltd. ThromboGenics NV AngioChem Inc. Ascenta Therapeutics, Inc. Vascular Biogenics Ltd. Archer Biosciences, Inc Tocagen Inc. DNAtrix, Inc. ERC Belgium SA OncoSynergy Inc For more information visit http://www.researchandmarkets.com/research/dcl2zl/recurrent About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Critical Alerts For AT&T, Mastercard, Disney, Du Pont, and Celldex Therapeutics Released By InvestorsObserver
PR Newswire - Wed Feb 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for T, MA, DIS, DD, and CLDX.
Celldex Announces Upcoming Presentation at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 06, 10:00AM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, and Tom Davis, M.D., Senior Vice President and Chief Medical Officer, are scheduled to present a corporate overview at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 2:40 pm ET at the Waldorf Astoria in New York City.
Inphi to Present at Stifel Nicolaus 2014 Technology, Internet & Media Conference
Marketwire - Wed Feb 05, 7:01AM CST
Inphi Corporation (NYSE: IPHI), a leading provider of high-speed mixed signal semiconductor solutions for the communications and computing markets, today announced that John Edmunds, Chief Financial Officer, will be presenting at the Stifel Nicolaus 2014 Technology, Internet & Media Conference on Tuesday, February 11, 2014 at 4:25 p.m. PT at The Fairmont Hotel in San Francisco, CA.
Northwest Bio's German Smokescreen Obscures DCVax Problems
at The Street - Tue Mar 11, 1:44PM CDT
Northwest Bio received good news from Germany in February but didn't tell investors until Monday.
Biotech Earnings Checkup: CLDX, DNDN, OPX
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Earnings are the lifeblood of a company. They speak to a company's past, present, and most importantly for investors, future. And they give an important window into the overall health of a company. So, with that in mind, let's dig into the earnings...
Personalized Medicine and Companion Diagnostic Market - 2014 Gives Details of their Operations, Products, Financials and Business Strategy
M2 - Thu Mar 06, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpc89x/personalized) has announced the addition of the "Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 263 tables & figures over 224 pages. The personalized medicine (global) market is presented as follows: -By Company -By Geography -By Segment -By Sub-market A wealth of financial data & business strategy information is provided including: -Up-to-date company financials, sales & revenue figures -Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies -Business Model Strategies for Providers. Provider Systems and Academic Medical Centres -Business Model Strategies for Payers & Governments -Private and Public Funding and Personalized Medicine Reimbursement -Revisions to Current Payment Systems and intellectual property -How to Gain Market Penetration in the EU -Cost-effectiveness and Business Value of Personalized Medicine -Consumer genomics and POC market -Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) -Comprehensive account of company product portfolios & kits This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. -23andMe -Affymetrix -Astex Pharmaceuticals -Atossa Genetics -CuraGen -Celera Corporation (Quest Diagnostics) -Celldex Therapeutics -deCode Genetics (Amgen) -Illumina -Genelex -Myriad -Nodality -Qiagen This report tackles key concerns to the personalized medicine market such as: -Lack of regulatory policy and legislation in the US and Europe -Reimbursement schemes and payers concerns -Transition of investigational diagnostic assays and therapeutics to clinical practice -Direct to consumer (DTC) test kits and implications for the public This detailed report is supported with 263 figures and tables over 224 pages and profiles the main pharmacos in personalized medicine. For more information visit http://www.researchandmarkets.com/research/rp...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Celldex Posts Narrower-Than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 10:30AM CST
Celldex' loss narrows in Q4
Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX)
at The Street - Tue Mar 04, 8:46AM CST
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Celldex Therapeutics (CLDX) in Focus: Stock Tumbles 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:56AM CST
Celldex Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell over 10% on the day.
American Realty Capital Properties and Cole Capital(TM) Name Michael Ezzell to Lead Private Capital Management Business
PR Newswire - Tue Mar 04, 5:00AM CST
American Realty Capital Properties, Inc. ("ARCP") and Cole Capital(TM), ARCP's private capital management business, jointly announced today the appointment of Michael Ezzell as Executive Vice President of Private Capital Markets.
Why Celldex Therapeutics Inc. Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 03, 12:27PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Celldex Therapeutics , a predominantly...
Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due
at The Street - Mon Mar 03, 9:32AM CST
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
Celldex Reports Fiscal 2013 Business/Financial Results and Outlines 2014 Strategy
GlobeNewswire - Mon Mar 03, 7:03AM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2013 and outlined the Company's major clinical development goals for 2014.
Celldex to Report Fourth Quarter and Fiscal 2013 Business/Financial Results and Host 2014 Strategy Conference Call
GlobeNewswire - Tue Feb 25, 12:30PM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year end 2013 financial results on Monday, March 3, 2014 before the U.S. financial markets open. Celldex executives will host a conference call at 8:30 a.m. ET on the same day to discuss 2013 financial and business results and to provide an update on key 2014 objectives.
Sumtra to add approval of property sale to annual meeting agenda
CNW Group - Sat Feb 22, 12:03PM CST
Sumtra Diversified Inc. (NEX Board: YSU.H) ("Sumtra" or the "Company") announced today that it plans to ask shareholders to also consider the approval of the sale of certain real property held by Sumtra (the "Property Sale") as other business at the Company's upcoming annual and special meeting of shareholders to be held in Toronto on Tuesday, February 25, 2014 (the "Meeting").
Celldex Therapeutics Rises 9.74% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Feb 21, 4:32PM CST
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $28.93 to a high of $31.83. Yesterday, the shares gained 9.7%, which took the trading range above the 3-day high of $29.14 on volume of 4.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
US Cancer Vaccine Market Outlook 2018 Research Report
M2 - Fri Feb 14, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/vmrhtt/us_cancer_vaccine) has announced the addition of the "US Cancer Vaccine Market Outlook 2018" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. The vaccine market, specifically the cancer vaccine market has remained resilient to the global economic crisis in contrast to many life science sectors, which were severely impacted. Owing to drying pipelines and increasing pressure from patent expirations, the big pharma companies recognized the vaccine market as a potential resource of investment. Cancer vaccines are known to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the demand for these vaccines. The US cancer vaccine market was estimated to be worth USD 14 billion in 2012. The market is expected to witness an increase of 1.5 million people being diagnosed with cancer annually. With such a rapid increase in the incidence, the US cancer vaccine market is expected to grow at a CAGR of 10% to surpass USD 20 billion by 2018. The market for cancer vaccine is in its growth stage in the US and has great opportunities for entry. The USA alone accounts for a dominating share of 50% as compared to a combined share of 50% accounted for by Europe and other regions. US Cancer Vaccine Market Outlook 2018 gives a comprehensive insight on following issues related to cancer vaccine market development in US: - Cancer Incidence & Prevalence - Cancer Vaccine Market Overview - Cancer Vaccine Pricing & Reimbursement Policy - Cancer Vaccine with Orphan Status - Cancer Vaccine Pipeline by Indication & Phase - Market Regulations - Company Overview & Vaccine Pipeline Key Topics Covered: US Cancer Incidence & Prevalence US Cancer Vaccine Market Outlook US Cancer Vaccine Market Dynamics US Cancer Vaccine Pipeline by Indication US Cancer Vaccine Pipeline by Clinical Phase US Cancer Vaccine Market Regulations Competitive Landscape: Business Overview & Vaccine Pipeline List of Tables and Figures Companies Mentioned - Aduro BioTech - Antigen Express - Bavarian Nordic - Celldex Therapeutics - Dendreon - GSK - Galena Biopharma - Merck & Co - Oxford BioMedica For more information visit http://www.researchandmarkets.com/research/vm...er_vaccine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Use Options For A Chance To Buy CLDX At A 62% Discount
at The Street - Thu Feb 13, 10:42AM CST
Looking back to 71 days ago, Celldex Therapeutics priced a 7,000,000 share secondary stock offering at $24.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the...
Monoclonal Antibodies Market in Breast Cancer to 2019: Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth
M2 - Thu Feb 13, 10:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/3fr5l8/monoclonal) has announced the addition of the "Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth" report to their offering. The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of these have also received further approvals in the early setting in order to improve long-term remission rates. The market is currently led by the HER-2 inhibitor Herceptin, which achieved global sales amounting to $6.2 billion in 2012. Over the forecast period from 2012 to 2019, the two novel HER-2 inhibitors, Kadcyla and Perjeta, are expected to achieve strong market penetration due to their appreciable incremental efficacy benefits. Additionally, the market conditions are currently favorable towards mAbs, with a low rate of price depreciation following patent expiry and a high rate of inflation for specialty pharmaceuticals in the US. As a result of this, and despite the empty Phase III pipeline, the authors believe that the global market across the leading eight countries have the potential to grow to a value of $10.6 billion by 2019. Key Topics Covered: 1. Tables & Figures 2 Introduction 3 Marketed Products 3.1 Herceptin (Trastuzumab) - Hoffmann La Roche 3.2 Avastin (Bevacizumab) - Hoffmann La Roche 3.3 Kadcyla (Trastuzumab Emtansine) - Hoffmann La Roche 3.4 Perjeta (Pertuzumab) - Hoffmann La Roche 3.5 Xgeva (denosumab) - Amgen 3.6 Heat Map for Marketed Products 3.7 Conclusion 4 Pipeline for Breast Cancer Monoclonal Antibody Therapeutics 4.1 Overall Pipeline 4.2 Mechanisms of Action 4.3 Clinical Trials 4.3.1 Attrition Rate 4.3.2 Clinical Trial Size 4.3.3 Duration 4.3.4 Clinical Trial End-points 4.4 Promising Drug Candidates in the Pipeline 4.4.1 CDX-011 (glembatumumab vedotin) - Celldex Therapeutics 4.4.2 Metmab (onartuzumab) - Hoffman La Roche 4.4.3 Hu3S193 - Recepta Biopharma 4.4.4 MM-121 - Merrimack Pharmaceuticals 4.4.5 IMC-18F1 (Icrucumab) - Eli Lilly 4.4.6 Rexomun (Ertumaxomab) - Fresenius Biotech 4.4.7 Medi-573 (Dusigitumab) - Medimmune 4.4.8 MK-0646 (Dalotuzumab) - Merck and Co 4.4.9 LY3012217 (Cixutumumab) - Eli Lilly 4.5 Conclusion 5 Market Forecast to 2019 5.1 Global 5.2 US 5.3 Canada 5.4 Europe 5.5 Japan 5.6 Drivers and Barriers 6 Deals and Strategic Consolidations 7 Appendix For more information visit http://www.researchandmarkets.com/research/3fr5l8/monoclonal
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013
M2 - Thu Feb 13, 2:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/dcl2zl/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013" report to their offering. 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM). Key Topics Covered: Introduction Recurrent Glioblastoma Multiforme (GBM) Overview Therapeutics Development Clinical Stage Products Early Stage Products Drug Profiles bosutinib - Drug Profile axitinib - Drug Profile onartuzumab - Drug Profile dacomitinib - Drug Profile rindopepimut - Drug Profile VB-111 - Drug Profile ANG-1005 - Drug Profile AT-101 - Drug Profile vorinostat - Drug Profile buparlisib hydrochloride - Drug Profile pazopanib hydrochloride - Drug Profile memantine hydrochloride - Drug Profile galunisertib - Drug Profile G-200 - Drug Profile ERC-1671 - Drug Profile lenvatinib - Drug Profile trebananib - Drug Profile TB-403 - Drug Profile nabiximols - Drug Profile golvatinib - Drug Profile ARC-100 - Drug Profile New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile vocimagene amiretrorepvec flucytosine ER - Drug Profile golvatinib lenvatinib - Drug Profile ICT-121 - Drug Profile BTSC mRNA Loaded Dendritic Cell Vaccine - Drug Profile AZD-7451 - Drug Profile DNX-2401 - Drug Profile OS-2966 - Drug Profile Recurrent Glioblastoma Multiforme (GBM) - Recent Pipeline Updates Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned F. Hoffmann-La Roche Ltd. Amgen Inc. AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Agenus, Inc. Merck & Co., Inc. Novartis AG Eisai Co., Ltd. Pfizer Inc. GW Pharmaceuticals plc Celldex Therapeutics, Inc. ImmunoCellular Therapeutics, Ltd. ThromboGenics NV AngioChem Inc. Ascenta Therapeutics, Inc. Vascular Biogenics Ltd. Archer Biosciences, Inc Tocagen Inc. DNAtrix, Inc. ERC Belgium SA OncoSynergy Inc For more information visit http://www.researchandmarkets.com/research/dcl2zl/recurrent About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Critical Alerts For AT&T, Mastercard, Disney, Du Pont, and Celldex Therapeutics Released By InvestorsObserver
PR Newswire - Wed Feb 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for T, MA, DIS, DD, and CLDX.
Celldex Announces Upcoming Presentation at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 06, 10:00AM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, and Tom Davis, M.D., Senior Vice President and Chief Medical Officer, are scheduled to present a corporate overview at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 2:40 pm ET at the Waldorf Astoria in New York City.
Inphi to Present at Stifel Nicolaus 2014 Technology, Internet & Media Conference
Marketwire - Wed Feb 05, 7:01AM CST
Inphi Corporation (NYSE: IPHI), a leading provider of high-speed mixed signal semiconductor solutions for the communications and computing markets, today announced that John Edmunds, Chief Financial Officer, will be presenting at the Stifel Nicolaus 2014 Technology, Internet & Media Conference on Tuesday, February 11, 2014 at 4:25 p.m. PT at The Fairmont Hotel in San Francisco, CA.
(0)
(0)Celldex Therapeutics Inc (CLDX) Stock Research Links
Scroll down for more posts ▼